Lannett is one step closer to launching biosimilar insulin glargine. Recently, the company completed subject dosing in the pivotal clinical trial of biosimilar insulin glargine, a product being ...
TREVOSE, Pa., Aug. 31, 2022 /PRNewswire/ -- Lannett Company, Inc. (LCI) today announced that subject dosing has been completed in the pivotal clinical trial of biosimilar insulin glargine, a product ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results